Objective:

Report TIME’s recognition of Essilor’s Stellest® lenses and the FDA regulatory milestones stated in the article.

Approach:

• Recognition: TIME named Stellest® lenses one of its Best Inventions in the Health & Wellness category.
• Regulatory status: The article states that the FDA granted Stellest® lenses De Novo market authorization in September 2025 and Breakthrough Device designation in 2021.

Key Findings:

• The article describes Stellest® as the first and only FDA market-authorized spectacle lenses in the United States to slow myopia progression in children.
• Arnaud Ribadeau Dumas, Head of Product & Marketing Optical Categories at EssilorLuxottica, called the TIME recognition “a strong acknowledgment of Essilor’s innovation capabilities.”

Interpretation:

The article says progressive myopia can affect long-term eye health and that regular eye exams and professional guidance are essential.

Limitations:

• The article provides no clinical study data or details about the evidence supporting the lenses.

Conclusion:

TIME named Essilor’s Stellest® lenses one of its Best Inventions in the Health & Wellness category. The article reports that the FDA granted the lenses De Novo market authorization in September 2025 and Breakthrough Device designation in 2021.